2,4-dibromoglutaric acid dibenzyl ester | 121050-01-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dibromoglutaric acid dibenzyl ester
• 英文别名: dibenzyl 2,4-dibromoglutarate；dibenzyl 2,4-dibromopentanedioate
• CAS: 121050-01-9
• 化学式: C₁₉H₁₈Br₂O₄
• 分子量: 470.158
• InChiKey: ZRBHQELLWPIETI-UHFFFAOYSA-N

物化性质

• 沸点：
  504.8±50.0 °C(Predicted)
• 密度：
  1.569±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-dibromoglutaric acid dibenzyl ester 在 甲醇 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 ((2R,4S)-1-benzylazetidine-2,4-diyl)dimethanol
  参考文献：
  名称：

  [EN] METHOD OF TREATMENT WITH 3-CYCLOPROPYLCARBONYL-3,6-DIAZABICYCLO[3.1.1]HEPTANE
  [FR] MÉTHODE DE TRAITEMENT PAR 3-CYCLOPROPYLCARBONYL-3,6-DIAZABICYCLO[3,1.1]HEPTANE

  摘要：

  本发明涉及3-环丙基甲酰基-3,6-二氮杂双环[3.1.1]庚烷，其盐形式，药物组合物和治疗方法。

  公开号：

  WO2014011863A1
• 作为产物：
  描述：

  戊二酰基二氯 在 溴 作用下， 以 乙醚 为溶剂， 生成 2,4-dibromoglutaric acid dibenzyl ester
  参考文献：
  名称：

  [EN] SALT FORMS OF 3 - CYCLOPROPYLCARBONYL - 3, 6 - DIAZABICYCLO [3.1.1] HEPTANE
  [FR] NOUVELLES FORMES SALINES DE 3-CYCLOPROPYLCARBONYL-3,6-DIAZABICYCLO[3.1.1]HEPTANE

  摘要：

  本发明涉及3-环丙基甲酰基-3,6-二氮杂双环[3.1.1]庚烷，其盐形式，以及这些盐的新型多形式。

  公开号：

  WO2012125518A1

文献信息

• Azetidine derivatives, compositions and methods of treating
  申请人：Fidia-Georgetown Institute for the Neurosciences

  公开号：US04946839A1

  公开（公告）日：1990-08-07

  This invention relates to novel azetidines and derivative thereof, as well as to pharmaceutical compositions and methods of treating memory and learning disorders. Another aspect of the invention relates to a method of utilizing the compounds and compositions as biological tools and materials for characterizing excitatory amino acid receptor systems. A further aspect of the invention relates to a method of treating PCP toxicity and abuse.

  本发明涉及新型的氮杂环丙烷及其衍生物，以及制备药物组合物和治疗记忆和学习障碍的方法。本发明的另一个方面涉及利用这些化合物和组合物作为生物学工具和材料，以表征兴奋性氨基酸受体系统的方法。本发明的另一个方面涉及治疗PCP毒性和滥用的方法。
• Azetidine derivatives to treat memory and learning disorders
  申请人：FIDIA-Georgetown Institute for the Neurosciences

  公开号：US04990504A1

  公开（公告）日：1991-02-05

  This invention relates to novel azetidines and derivatives thereof, as well as to pharmaceutical compositions and methods of treating memory and learning disorders. Another aspect of the invention relates to a method of utilizing the compounds and compositions as biological tools and materials for characterizing excitatory amino acid receptor systems. A further aspect of the invention relates to a method of treating PCP toxicity and abuse.

  本发明涉及新型氮杂四环和其衍生物，以及制备药物组合物和治疗记忆和学习障碍的方法。本发明的另一个方面涉及利用这些化合物和组合物作为生物工具和材料，用于表征兴奋性氨基酸受体系统的方法。本发明的另一个方面涉及一种治疗PCP毒性和滥用的方法。
• Azetidine derivatives, compositions and their use
  申请人：FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES

  公开号：EP0299513A1

  公开（公告）日：1989-01-18

  This invention relates to novel azetidines and derivatives thereof, as well as to pharmaceutical compositions and their use for treating memory and learning disorders. Another aspect of the invention relates to a method of utilizing the compounds and compositions as biological tools and materials for characterizing excitatory amino acid receptor systems. A further aspect of the invention relates to a method of treating PCP toxicity and abuse.

  本发明涉及新型氮杂环丁烷及其衍生物，以及药物组合物及其用于治疗记忆和学习障碍的用途。本发明的另一方面涉及一种利用这些化合物和组合物作为生物工具和材料来表征兴奋性氨基酸受体系统的方法。本发明的另一方面涉及一种治疗五氯苯酚毒性和滥用的方法。
• Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake
  作者：Derong Ding、Justin R. Nickell、Agripina G. Deaciuc、Narsimha Reddy Penthala、Linda P. Dwoskin、Peter A. Crooks

  DOI：10.1016/j.bmc.2013.08.001

  日期：2013.11

  Lobelane analogs that incorporate a central piperidine or pyrrolidine moiety have previously been reported by our group as potent inhibitors of VMAT2 function. Further central ring size reduction of the piperidine moiety in lobelane to a four-membered heterocyclic ring has been carried out in the current study to afford novel cis-and trans-azetidine analogs. These azetidine analogs (15a-15c and 22a-22c) potently inhibited [H-3]dopamine (DA) uptake into isolated synaptic vesicles (K-i <= 66 nM). The cis-4-methoxy analog 22b was the most potent inhibitor (K-i = 24 nM), and was twofold more potent that either lobelane (2a, K-i = 45 nM) or norlobelane (2b, K-i = 43 nM). The trans-methylenedioxy analog, 15c (K-i = 31 nM), was equipotent with the cis-analog, 22b, in this assay. Thus, cis-and trans-azetidine analogs 22b and 15c represent potential leads in the discovery of new clinical candidates for the treatment of methamphetamine abuse. (C) 2013 Elsevier Ltd. All rights reserved.
• Synthesis and bioactivity of a new class of rigid glutamate analogs. Modulators of the N-methyl-D-aspartate receptor
  作者：Alan P. Kozikowski、Werner Tuckmantel、Ian J. Reynolds、Jarda T. Wroblewski

  DOI：10.1021/jm00168a007

  日期：1990.6

  A variety of derivatives of azetidine-2,4-dicarboxylic acid were synthesized and examined for their ability to stimulate 45Ca2+ uptake in cultures of cerebellar granule cells. Of the compounds tested, the cis-azetidine-2,4-dicarboxylic acid (10f) was found to be the most potent agent in potentiating glutamate, aspartate, or N-methyl-D-aspartate (NMDA) stimulated 45Ca2+ uptake at the NMDA receptor. The mechanism of action of 10f was further investigated in [3H]MK-801 binding assays and [3H]GABA release from cultured embryonic rat forebrain neurons. All of the results from the functional studies of azetidine 10f are consistent with a selectivity of action at the NMDA receptor. Moreover, azetidine 10f appears to exhibit a dual type of action, behaving as a glutamate-like agonist at higher concentrations and as a positive modulator at concentrations below 50 microM.